Mattia Arrigo

Mattia Arrigo

Auto-generated profile, based on publicly available information

Mattia Arrigo

Ospedale Regionale di Lugano

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2020 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
OCOvidiu Chioncel
Ovidiu Chioncel
JPJohn Parissis
John Parissis
AMAlexandre Mebazaa
Alexandre Mebazaa
HTHolger Thiele
Holger Thiele
SDSteffen Desch
Steffen Desch
PSPetar Seferovic
Petar Seferovic
Cardiogenic shock (CS) is a complex multifactorial clinical syndrome with extremely high mortality, developing as a continuum, and progressing from the initial insult (underlying cause) to the subsequent occurrence of organ failure and death. There is a large spectrum of CS presentations resulting from the interaction between an acute cardiac insult and a patient’s underlying cardiac and overall medical condition. Phenotyping patients with CS may have clinical impact on management because classification would support initiation of appropriate therapies. CS management should consider appropriate organization of the health care services, and therapies must be given to the appropriately selected patients, in a timely manner, whilst avoiding iatrogenic harm. Although several consensus-driven algorithms have been proposed, CS management remains challenging and substantial investments in research and development have not yielded proof of efficacy and safety for most of the therapies tested, and outcome in this condition remains poor. Future studies should consider the identification of the new pathophysiological targets, and high-quality translational research should facilitate incorporation of more targeted interventions in clinical research protocols, aimed to improve individual patient outcomes. Designing outcome clinical trials in CS remains particularly challenging in this critical and very costly scenario in cardiology, but information from these trials is imperiously needed to better inform the guidelines and clinical practice. The goal of this review is to summarize the current knowledge concerning the definition, epidemiology, underlying causes, pathophysiology and management of CS based on important lessons from clinical trials and registries, with a focus on improving in-hospital management.

23 June 2016 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
JBJohann G. Bauersachs
Johann G. Bauersachs
MAMattia Arrigo
Mattia Arrigo
DHDenise Hilfiker-Kleiner
Denise Hilfiker-Kleiner
CVChristian Veltmann
Christian Veltmann
ACAndrew J.S. Coats
Andrew J.S. Coats
KSKaren Sliwa
Karen Sliwa

14 September 2015 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
AMAlexandre Mebazaa
Alexandre Mebazaa
HTH. Tolppanen
H. Tolppanen
CMC. Mueller
C. Mueller
JLJ. Lassus
J. Lassus
SDS. DiSomma
S. DiSomma
JJJ. Januzzi
J. Januzzi

4 November 2019 in Cardiac Failure Review
Verified
Journal Article
Open access
PDF file
MAMattia Arrigo
Mattia Arrigo
LHLars Christian Huber
Lars Christian Huber
SWStephan Winnik
Stephan Winnik
FMFran Mikulicic
Fran Mikulicic
FGFederica Guidetti
Federica Guidetti
FRFrank Ruschitzka
Frank Ruschitzka
The prognostic significance of the right ventricle (RV) has recently been recognised in several conditions, primarily those involving the left ventricle, the lungs and their vascular bed, or the right-sided chambers. Recent advances in imaging techniques have created new opportunities to study RV anatomy, physiology and pathophysiology, and contemporary research efforts have opened the doors to new treatment possibilities. Nevertheless, the treatment of RV failure remains challenging. Optimal management should consider the anatomical and physiological particularities of the RV and include appropriate imaging techniques to understand the underlying pathophysiological mechanisms. Treatment should include rapid optimisation of volume status, restoration of perfusion pressure and improvement of myocardial contractility and rhythm, and, in case of refractory RV failure, mechanical circulatory support.

28 October 2016 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
MAMattia Arrigo
Mattia Arrigo
EGEtienne Gayat
Etienne Gayat
JPJiri Parenica
Jiri Parenica
SIShiro Ishihara
Shiro Ishihara
JZJian Zhang
Jian Zhang
ONOn Behalf Of The Great Network
On Behalf Of The Great Network
Aims Several clinical conditions may precipitate acute heart failure (AHF) and influence clinical outcome. In this study we hypothesized that precipitating factors are independently associated with 90‐day risk of death in AHF. Methods and results The study population consisted of 15 828 AHF patients from Europe and Asia. The primary outcome was 90‐day all‐cause mortality according to identified precipitating factors of AHF [acute coronary syndrome (ACS), infection, atrial fibrillation (AF), hypertension, and non‐compliance]. Mortality at 90 days was 15.8%. AHF precipitated by ACS or by infection showed increased 90‐day risk of death compared with AHF without identified precipitants [hazard ratio (HR) 1.69, 95% confidence interval (CI) 1.44–1.97, P < 0.001; and HR 1.51, 95% CI 1.18–1.92, P = 0.001), while AHF precipitated by AF showed lower 90‐day risk of death (HR 0.56, 95% CI 0.42–0.75, P < 0.001), after multivariable adjustment. The risk of death in AHF precipitated by ACS was the highest during the first week after admission, while in AHF precipitated by infection the risk of death had a delayed peak at week 3. In AHF precipitated by AF, a trend toward reduced risk of death during the first weeks was shown. At weeks 5–6, AHF precipitated by ACS, infection, or AF showed similar risk of death to that of AHF without identified precipitants. Conclusions Precipitating factors are independently associated with 90‐day mortality in AHF. AHF precipitated by ACS or infection is independently associated with higher, while AHF precipitated by AF is associated with lower 90‐day risk of death.

18 December 2017 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
LALucas N.L. Van Aelst
Lucas N.L. Van Aelst
MAMattia Arrigo
Mattia Arrigo
RPRui Placido
Rui Placido
EAEiichi Akiyama
Eiichi Akiyama
NGNicolas Girerd
Nicolas Girerd
MSMarie-France Seronde
Marie-France Seronde